Real-World Safety and Effectiveness of Adalimumab in Patients with Non-Infectious Intermediate, Posterior, or Panuveitis: A Post-Marketing Surveillance Study in Korea.
PURPOSE This post-marketing surveillance study reports the real-world safety and effectiveness of adalimumab (Humira®, AbbVie Inc.) among patients with non-infectious intermediate, posterior, or panuveitis (NIIPPU) in Korea. METHODS The study was conducted at 17 medical centres from January 2018 to July 2020. Safety...